Skip to search formSkip to main contentSkip to account menu

50 ML olaratumab 10 MG/ML Injection [Lartruvo]

Known as: Lartruvo 500 MG in 50 ML Injection, Lartruvo 500 MG per 50 ML Injection, olaratumab 10 mg in 1 mL INTRAVENOUS SOLUTION [LARTRUVO] 
National Institutes of Health

Related topics

Related topics

10 relations
GlycineHistidineInjectionMannitol

Broader (1)

Lartruvo Injectable Product

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Información relacionada con el tratamiento con Olaratumab (▼ Lartruvo®): resultados del estudio posautorización requerido por las autoridades sanitaria
Review
2018
Review
2018
Developments in the management of advanced soft-tissue sarcoma – olaratumab in context
Lartruvo® (olaratumab) is a fully human immunoglobulin G subclass 1 (IgG1) monoclonal antibody that inhibits platelet-derived… 
2017
2017
Olaratumab (▼lartruvo®): Sarcoma de tejidos blandos
2017
2017
Olaratumab (LARTRUVO®) jako nowa opcja terapeutyczna w leczeniu zaawansowanych mięsaków tkanek miękkich
Olaratumab to nowo zarejestrowane do leczenia ludzkie przeciwcialo monoklonalne klasy IgG1 przeciwko receptorowi plytkopochodnego… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)